Developing strategic game plans in response to shifts in federal policy
How Federal Policy is Reshaping Biopharma Strategies
A Case Study on Navigating the Inflation Reduction Act (IRA)
The Inflation Reduction Act of 2022 introduces sweeping changes to prescription drug pricing, Medicare coverage, and reimbursement policies, fundamentally impacting the biopharmaceutical industry.
In this case study, Magnolia Market Access uncovers how biopharmaceutical manufacturers can:
- Interpret IRA Guidelines: Break down key provisions, timelines, and regulatory implications.
- Understand Payer Perspectives: Discover how payers are preparing for 2024 and adapting formularies, contracts, and utilization management strategies.
- Quantify the Economic Impact: Analyze pricing shifts, portfolio costs, and pipeline product implications under the IRA.
Download the case study to see how manufacturers are adapting to federal policy changes and preparing for the future.
